BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ryan M, Donato BMK, Irish W, Gasteyger C, L'Italien G, Laurence J. Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome. Pharmacoeconomics 2020;38:307-13. [PMID: 31828738 DOI: 10.1007/s40273-019-00862-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Williams K, Aggio D, Chen P, Anokhina K, Lloyd AJ, Wang Y. Utility Values Associated with Atypical Hemolytic Uremic Syndrome-Related Attributes: A Discrete Choice Experiment in Five Countries. Pharmacoeconomics 2021;39:901-12. [PMID: 34195967 DOI: 10.1007/s40273-021-01059-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 White A, Martin R, Sew K, Stucke A, Cook R. Economic impact of a rapid, on‐demand ADAMTS‐13 activity assay for the diagnosis of thrombotic thrombocytopenic purpura. Res Pract Thromb Haemost 2022;6. [DOI: 10.1002/rth2.12711] [Reference Citation Analysis]
3 Chung C. New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab. Ann Pharmacother 2021;55:330-43. [PMID: 32715723 DOI: 10.1177/1060028020941852] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Coelho Júnior JL, Israel KCP, Machado CEE, Muniz MPR, Gatto GC, Barros FHS, Cunha KA, de Lacerda MVG, Neves PDMM, Silva GEB. Thrombotic microangiopathy associated with arboviral infection: Report of 3 cases. PLoS Negl Trop Dis 2021;15:e0009790. [PMID: 34648498 DOI: 10.1371/journal.pntd.0009790] [Reference Citation Analysis]
5 Wu S, Cui X, Zhang S, Tian W, Liu J, Wu Y, Wu M, Han Y. Economic burden of readmission due to postoperative cerebrospinal fluid leak in Chinese patients. J Comp Eff Res 2020;9:1105-15. [PMID: 33112181 DOI: 10.2217/cer-2020-0067] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]